Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer's disease and Parkinson's disease) and pancreas (Type 2 diabetes). Antibodies, which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of toxic protein particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in Alzheimer's, Parkinson's, and other disorders.
To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potently inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two target proteins per antibody. Antibodies created using Tessier's method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer's and Parkinson's.
"It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient's blood stream will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer's and Parkinson's disease," said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. "Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system."
Results of the new study, titled "Rational design of potent domain antibody inhibitors of amyloid fibril assembly," were published online last week by the journal Proceedings of the National Academy of Sciences (PNAS). The study may be viewed at: http://www.pnas.org/content/early/2012/11/14/1208797109.abstract
Rensselaer Polytechnic Institute: http://www.rpi.edu/News
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
If we want to understand whats happening in the brain when people hear voices, we first need to understand what happens during ordinary inner speechHearing voices: whats your experience when reading?
Seals and sea lions may have brought a form of tuberculosis to the Americas, centuries before the Spanish did so
More people with non-fatal conditions are travelling to assisted dying clinics in Switzerland
We’re all born to adore ourselves, but not all of us grow up
Rumours of dubious treatments are spreading on social media in West Africa, while fishy Ebola treatments are being peddled to anxious US citizens
The type of Ebola erupting in West Africa is closely related to one found 2,500 miles away — the distance between Boston and San Francisco. How did the virus spread so far without anyone noticing?
The tendency of Clostridium novyi to kill mammal cells has been used to shrink tumours in dogs and people, so the bacteria could help fight some cancers
The Burns Collection consists of human cadavers from the early 1800s that were anatomically dissected and preserved to teach anatomy and surgery to medical students. For the first time this portion of the collection is on display to the public as a part of traveling exhibit "Mummies of the World: The Exhibition."
Author Adam Rogers says there are lots of myths about what causes hangovers. His new book, Proof: The Science of Booze, explores these and other scientific mysteries of alcohol's effect on the body.
An experimental vaccine being developed by U.S. government scientists to prevent the painful mosquito-borne viral disease chikungunya has shown promise in its first human trials but remains years away from approval for widespread use.